Janssen’s Remicade Patent Invalid According to Massachusetts Court

Massachusetts Federal district court ruled that Janssen Biotech, Inc.’s US Patent No. 6,284,471 for Remicade (infliximab) is invalid. Janssen will appeal to the CAFC.

“Janssen loses patent fight over arthritis drug“

“Celltrion, Hospira receive favourable ruling from Massachusetts court on Remicade patent; J&J to appeal“

Leave a Reply Cancel reply

You must be logged in to post a comment.

Exit mobile version